China’s biotech rise has been a persistent concern for federal health leaders, Congress, and many biopharma executives. But to Roivant CEO Matt Gline, the country is nothing more than a red herring. 

In this week’s episode of "The Top Line," Fierce Biotech’s Darren Incorvaia chats with Gline about China, artificial intelligence and the exciting year ahead for Roivant’s lead asset brepocitinib. 

To learn more about the topics in this episode: 

• After 230% deal size explosion, China is no longer the 'bargain basement' for biopharma licensing: analyst 

• NIH grant cuts hit women, early-career scientists the hardest: analysis 

• Roche pumps $480M into South Korea biopharma industry to establish global trial 'ecosystem' 

• Lilly pledges $500M to South Korea biopharma industry, following Roche’s lead 

• Pfizer-backed Priovant scores again with fast-rising brepocitinib in midstage study